Review article: The need for more efficient and patient‐oriented drug development pathways in NASH—setting the scene for platform trials

Non‐alcoholic steatohepatitis (NASH) constitutes a significant unmet medical need with a burgeoning field of clinical research and drug development. Platform trials (PT) might help accelerate drug development while lowering overall costs and creating a more patient‐centric environment. This review provides a comprehensive and nuanced assessment of the NASH clinical development landscape.

[1]  F. Tacke,et al.  Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and Cons. , 2022, Journal of hepatology.

[2]  Marta Bofill Roig,et al.  On model-based time trend adjustments in platform trials with non-concurrent controls , 2021, BMC Medical Research Methodology.

[3]  A. Khosla,et al.  A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH , 2021, Hepatology.

[4]  M. Desai,et al.  Clinical trials in a COVID-19 pandemic: Shared infrastructure for continuous learning in a rapidly changing landscape , 2021, Clinical trials.

[5]  A. Sanyal,et al.  Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study , 2020, The Patient - Patient-Centered Outcomes Research.

[6]  R. Ritchie,et al.  Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments , 2020, Frontiers in Pharmacology.

[7]  M. Allison,et al.  The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. , 2020, Contemporary clinical trials.

[8]  P. Bedossa,et al.  An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials , 2020, Diagnostics.

[9]  M. Posch,et al.  The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. , 2020, Clinical therapeutics.

[10]  G. Koch,et al.  Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. , 2020, Journal of hepatology.

[11]  V. Miller,et al.  Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations from the Liver Forum. , 2020, Journal of hepatology.

[12]  T. Okanoue,et al.  Current and new pharmacotherapy options for non-alcoholic steatohepatitis , 2020, Expert opinion on pharmacotherapy.

[13]  F. Beyer,et al.  Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis , 2020, JHEP reports : innovation in hepatology.

[14]  V. Wong,et al.  Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials. , 2020, Journal of hepatology.

[15]  N. Bhala,et al.  Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.

[16]  M. Sydes,et al.  Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement , 2020, British Journal of Cancer.

[17]  A. Tzallas,et al.  High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  H. Conjeevaram,et al.  Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension. , 2019, Gastroenterology.

[19]  F. Tacke,et al.  New drugs for NAFLD: lessons from basic models to the clinic , 2019, Hepatology International.

[20]  Hongliang Li,et al.  Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease , 2019, Trends in Endocrinology & Metabolism.

[21]  F. Tacke,et al.  Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD , 2019, Hepatology.

[22]  Karl Broich,et al.  Master protocols in clinical trials: a universal Swiss Army knife? , 2019, The Lancet. Oncology.

[23]  D. Rockey,et al.  Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. , 2018, Gastroenterology.

[24]  B. Neuschwander‐Tetri,et al.  Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science , 2017, Hepatology.

[25]  J. Woodcock,et al.  Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. , 2017, The New England journal of medicine.

[26]  Robert Blissett,et al.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe , 2016, Hepatology.

[27]  S. Berry,et al.  Efficiencies of platform clinical trials: A vision of the future , 2016, Clinical trials.

[28]  D. Berry,et al.  Emerging innovations in clinical trial design , 2016, Clinical pharmacology and therapeutics.

[29]  S. Friedman,et al.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop , 2015, Hepatology.

[30]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[31]  V. Wong,et al.  Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease , 2020 .